Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET

Company Participants

Hayleigh Collins - Director and Head of Corporate Communications

Sean Nolan - Chief Executive Officer

Sukumar Nagendran - President and Head of Research and Development

Kamran Alam - Chief Financial Officer

Conference Call Participants

Whitney Ijem - Canaccord Genuity

Kristen Kluska - Cantor Fitzgerald

Salveen Richter - Goldman Sachs

Gil Blum - Needham & Co

Yanan Zhu - Wells Fargo Securities

Jack Allen - Baird

Joon Lee - Truist Securities

Silvan Tuerkcan - JMP Securities

Operator

Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer will follow the formal presentation. [Operator Instructions] Please note that this call is being recorded.

I would now like to turn the call over to Hayleigh Collins, Director, Head of Corporate Communications and Investor Relations. Thank you and you may proceed, Hayleigh.

Hayleigh Collins

Thank you. Good afternoon and welcome to Taysha’s third quarter 2023 financial results and corporate update conference call. Earlier today, Taysha issued a press release announcing financial results for the third quarter 2023. A copy of this press release is available on the Company's website and through our SEC filings.

Joining me on today's call are Sean Nolan, Taysha's CEO; Sukumar Nagendran, President and Head of R&A; Kamran Alam, Chief Financial Officer. We will hold a question-and-answer session following our prepared remarks.

Please note that on today's call, we will be making forward-looking statements including statements relating to the therapeutic and commercial potential of TSHA-102 including the reproducibility and durability of any favorable results initially seen in our first and second patients dosed in the REVEAL trial and including our preclinical product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat in our research, development and regulatory plans for our product candidates.

These statements may include the expected timing and results of clinical trials for our product candidates and other clinical and regulatory plans, and the market opportunity for those programs. This call may also contain forward-looking statements relating to Taysha’s growth, forecasted cash runway in future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not historical facts or information.

Various risks may Taysha's actual results to differ materially from those stated or implied in such forward-looking statements. These risks include uncertainties related to the timing and results of clinical trials and regulatory interactions for our product candidates are dependents upon strategic alliances and other third party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties, and the requirements of substantial funding to conduct our research and development activities.